NTB003

NTB003 is a second-generation, fully human anti-IGF-1R monoclonal antibody developed for the treatment of Thyroid Eye Disease (TED). It was co-developed by Biocytogen and Nanjing Chia Tai Tianqing. The antibody was discovered and optimized using Biocytogen’s RenMab™ platform, while Nanjing Chia Tai Tianqing handled process development and regulatory submissions. Compared to first-generation anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies show potent signal-blocking activity and effective inhibition of hyaluronic acid release. The drug has received IND approval in China for TED[1][3][5][10].